I am happy to report that our year ended with a positive result of 4.164, which is 12.474 lower than we anticipated in our budget. From our overall income of 1.329.271,25 we report 976.387 to 2022 as like last year, we defer income received into 2023 to support ongoing and planned activities especially in projects.
Our income has remained stable compared to 2021, when we had the leap increase of income 200.000. This is exactly at the same pace as the need for resources and support our work for patients with allergies, asthma and COPD at European level. However, our work is continuous, while the financial year is a calendar year, which is forcing us to have annual projects with 12 months duration, which start in latter part of Q1 or in Q2 due to late securing of budget. This also explains the need to defer monies.
Behind the numbers, which mean that we secured the resources we need for the activities, and spent them accordingly, there are many things which went differently than planned. We welcomed one new corporate funding partner and secured one that was not budgeted. At the same time, we lost two partners, due to their change of direction. We joined two important and successful research project bids to the EU Research programme Horizon, and received funding to support patient perspective in two important projects TOLIFE on COPD and SynAir-G on indoor air quality and children with allergy and asthma.
Our financial situation is healthy, which secures sustainable partnerships, accountability and continuity of our work at European level for patients with allergies, asthma and COPD. This is only possible due to our funders. I thank you warmly and sincerely.
I, as treasurer, will be ending my term in 2023, and I remember especially those moments when I met in person my board colleagues, the office team and our funders in Brussels in our hybrid meeting, and fellow members in our Re-Union in Iceland. What a community this is. It is good to see the commitment and determination to drive, and to support greater prioritisation for patients with our prevalent allergies, asthma and COPD.
Yvonne Spies, Treasurer